CheckMate 77T

Prespecified interim analysis results from CheckMate 77T trial of neoadjuvant nivolumab or placebo plus chemotherapy and adjuvant nivolumab or placebo in stage II to IIIB NSCLC, as presented at ESMO Congress 2023 and reported by Clinical Care Options (CCO)

PharmaScroll on LinkedIn: Phase 3 Trial Shows Neoadjuvant

Dr. Antonio Calles 🫁🚭 on X: CHECKMATE-77T: Neoadjuvant chemo

Evolution of Combination Therapies for Clinical Stage IIIA Non

ESMO Abstract Leak Reveals Promising NSCLC Therapies from BMS

New data support perioperative nivolumab for NSCLC

Bristol Myers Squibb Announces Perioperative Regimen of

Nivolumab regimen improves outcomes in resectable non-small cell

Presurgery Opdivo + Chemo Cut Risk of Death by 43%

CheckMate-77T Trial Meets Primary EFS End Point in Resectable NSCLC